R9Q Stock Overview
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.29 |
| 52 Week High | AU$0.38 |
| 52 Week Low | AU$0.23 |
| Beta | 1.05 |
| 11 Month Change | 6.52% |
| 3 Month Change | 0.68% |
| 1 Year Change | 10.53% |
| 33 Year Change | -48.42% |
| 5 Year Change | n/a |
| Change since IPO | -9.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| R9Q | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -0.8% | -1.0% |
| 1Y | 10.5% | -11.6% | 12.8% |
Return vs Industry: R9Q exceeded the German Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: R9Q matched the German Market which returned 12.8% over the past year.
Price Volatility
| R9Q volatility | |
|---|---|
| R9Q Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R9Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R9Q's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Recce Pharmaceuticals Ltd Fundamentals Summary
| R9Q fundamental statistics | |
|---|---|
| Market cap | €74.62m |
| Earnings (TTM) | -€10.94m |
| Revenue (TTM) | €3.12m |
24.0x
P/S Ratio-6.8x
P/E RatioIs R9Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R9Q income statement (TTM) | |
|---|---|
| Revenue | AU$5.03m |
| Cost of Revenue | AU$7.22m |
| Gross Profit | -AU$2.19m |
| Other Expenses | AU$15.47m |
| Earnings | -AU$17.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | -43.52% |
| Net Profit Margin | -351.24% |
| Debt/Equity Ratio | -101.7% |
How did R9Q perform over the long term?
See historical performance and comparison